Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tigilanol tiglate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tigilanol tiglate overview
Tigilanol tiglate (EBC-46) is under development for the treatment of refractory cutaneous or subcutaneous tumors of squamous cell carcinoma of head and neck, squamous cell carcinoma of the skin and Merkel cell tumors of the skin, basal cell carcinoma, breast cancer, metastatic colorectal cancer, angiosarcoma, adenocarcinoma, fibrosarcoma, adenoid cystic sarcoma, atypical fibroxanthoma, salivary gland cancer, sino-nasal cancers and laryngeal cancer. It is administered through intratumoral route. The drug candidate is a tiglien-3-one derivative. It acts by targeting protein kinase C (PKC). The drug candidate is developed based on EcoLogic technology.
It was also under development for the treatment of melanoma
QBiotics Group overview
QBiotics Group discovers and develops plant-derived cell signalling molecules to treat diseases in humans and companion animals. The company is investigating tigilanol tiglate, a novel small molecule that is delivered into the tumor cells to treat head and neck squamous cell carcinoma, melanoma and soft tissue sarcoma; EBC-1013, a novel semi-synthetic small molecule topical gel to heal venous leg ulcer and burns; and antibiotics targeting multiple drug resistant bacteria. It is also developing therapies for canine soft tissue sarcoma, equine sarcoids and equine acute and chronic wounds in animals. The company utilizes its proprietary discovery platform EcoLogic, to develop drugs by anticipating cell signalling pathways in plant-environment, plant-animal and plant-microbe interactions. QBiotics Group is headquartered in Yungaburra, Queensland, Australia.
For a complete picture of Tigilanol tiglate’s drug-specific PTSR and LoA scores, buy the report here.